The RIDASCREEN® UST Monitoring is an enzyme linked immunosorbent assay intended for the quantitative determination of ustekinumab (UST, Stelara®) in human serum and plasma.
Ustekinumab (UST, Stelara®) is a fully human monoclonal antibody that binds to the p40 subunit common to IL-12 and IL-23 thereby preventing the interaction with the cytokine receptors on T cells, natural killer cells and antigen-presenting cells.UST has been approved for treatment of moderate to severe Crohn’s disease (CD), plaque psoriasis and psoriatic arthritis.
The RIDASCREEN® UST Monitoring and our other TDM assays are vital to personalize treatment of patients to achieve better therapeutic targets.
- CE-marked version of the ELISA tests of KU Leuven
- Highly specific antibodies
- Ready to use reagents
- Validated for use on automated ELISA systems, e.g. the Dynex DSX®
|Test format||Microtiter plate with 96 wells (12 strips with 8 removable wells each)|
|Incubation time||1 h 40 min|